Palisade Bio (PALI) Net Equity Issued and Repurchased (2010 - 2026)

Palisade Bio (PALI) has reported Net Equity Issued and Repurchased for 14 consecutive years, with $3.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $131.5 million (up 1458.61% YoY), while the FY2025 annual figure was $128.2 million, up 1420.08% from the prior year.
• Net Equity Issued and Repurchased slipped to $3.2 million in Q1 2026 per PALI's latest filing, from $128.2 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $128.2 million in Q4 2025 and bottomed at $1.7 million in Q3 2023.
• Historically, Net Equity Issued and Repurchased has averaged $18.2 million across 5 years, with a median of $4.0 million in 2024.
• Annual changes were most pronounced in 2023 — Net Equity Issued and Repurchased slumped 86.23% — and 2025, when it jumped 2791.07%.
• Palisade Bio's Net Equity Issued and Repurchased stood at $12.6 million in 2022, then plunged by 86.23% to $1.7 million in 2023, then soared by 155.18% to $4.4 million in 2024, then surged by 2791.07% to $128.2 million in 2025, then tumbled by 97.47% to $3.2 million in 2026.
• Business Quant data shows PALI's Net Equity Issued and Repurchased at $3.2 million in Q1 2026, $128.2 million in Q4 2025, and $4.4 million in Q4 2024.